Company Fact Sheet – June 2019

Headquarters:	Nuvaira, Inc. 3750 Annapolis Lane North Suite 105 Minneapolis, MN 55447 763.450.2800 www.nuvaira.com
Number of Employees:	50
Products and Intended use:	The Nuvaira® Lung Denervation System is a novel, catheter-based system designed to treat airway nerve hyperactivity, a common pathophysiologic underpinning of chronic obstructive pulmonary disease (COPD) and asthma. The Nuvaira system is comprised of a console and single use treatment package that contains the dNerva® Dual Cooled RF Catheter.
Procedure:	TLD therapy is delivered in a non-surgical procedure under general anesthesia. The TLD catheter is introduced through a bronchoscope through the mouth and into the airways of the lung. Energy is delivered at depth to ablate the vagal pulmonary nerves while continuously cooling and protecting the outer airways. Both lungs are treated in one procedure, which takes about an hour. TLD leaves no foreign body implants in the lung, and most patients are able to return home the day of the procedure.
Clinical Trials:	To date 184 patients have been followed in 3 completed clinical trials which have shown a long-term positive safety profile, feasibility, and clinical efficacy of targeted lung denervation in patients with COPD. AIRFLOW-3 is a 400-patient multinational, 1:1 randomized, sham-controlled, double-blinded pivotal trial that will begin enrollment in 2019.
Therapeutic Value Proposition:	The goal of TLD treatment is to improve clinical stability and reduce exacerbations in moderate-to-severe COPD patients with high symptom burden despite optimal medical management.
Regulatory Approvals:	CE mark (2016) Investigational Device Exemption (IDE) approval for the AIRFLOW-3 pivotal trial (2018)
Financing:	$151 million raised
Intellectual Property:	+ 75 patents issued and pending worldwide
Media Inquiries:	Amy Wolter +1 (763) 450-5676 info@nuvaira.com

###